Loading
A phase 1/2 trial of Acalabrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia is a phase 1/2 interventional study registered as NCT02029443 by Acerta Pharma BV, with 306 participants enrolled, started 2014-01-30 and due to reach its primary completion in 2021-07-15. Interventions recorded: Acalabrutinib. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
306 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2022-09-10), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) in Phase 1primary | Cohort 1 | 9 | 0 participants | - | - | link |
| Cohort 2a | 8 | 0 participants | ||||
| Cohort 2b | 29 | 0 participants | ||||
| Cohort 3 | 7 | 0 participants | ||||
| Cohort 4a | 6 | 0 participants | ||||
| Cohort 4b | 6 | 0 participants |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/